Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
206.54
+6.58 (3.29%)
At close: Dec 10, 2025, 4:00 PM EST
207.00
+0.46 (0.22%)
After-hours: Dec 10, 2025, 7:59 PM EST
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 31, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
$667,263
Profits / Employee
$181,890
Market Cap
497.62B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Dec 31, 2022 | 152,700 | 11,000 | 7.76% |
| Dec 31, 2021 | 141,700 | 7,200 | 5.35% |
| Dec 31, 2020 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | 132,200 | -2,900 | -2.15% |
| Dec 30, 2018 | 135,100 | 1,100 | 0.82% |
| Dec 31, 2017 | 134,000 | 7,600 | 6.01% |
| Dec 31, 2016 | 126,400 | -700 | -0.55% |
| Dec 31, 2015 | 127,100 | 600 | 0.47% |
| Dec 28, 2014 | 126,500 | -1,600 | -1.25% |
| Dec 29, 2013 | 128,100 | 500 | 0.39% |
| Dec 30, 2012 | 127,600 | 9,700 | 8.23% |
| Dec 31, 2011 | 117,900 | 3,900 | 3.42% |
| Dec 31, 2010 | 114,000 | -1,500 | -1.30% |
| Dec 31, 2009 | 115,500 | -3,200 | -2.70% |
| Dec 28, 2008 | 118,700 | -500 | -0.42% |
| Dec 30, 2007 | 119,200 | -3,000 | -2.45% |
| Dec 31, 2006 | 122,200 | 6,600 | 5.71% |
| Dec 31, 2005 | 115,600 | 5,600 | 5.09% |
| Dec 31, 2004 | 110,000 | -1,000 | -0.90% |
| Dec 28, 2003 | 111,000 | 3,000 | 2.78% |
| Dec 29, 2002 | 108,000 | 6,000 | 5.88% |
| Dec 30, 2001 | 102,000 | 1,000 | 0.99% |
| Dec 31, 2000 | 101,000 | 3,200 | 3.27% |
| Dec 31, 1999 | 97,800 | 4,700 | 5.05% |
| Dec 31, 1998 | 93,100 | 2,600 | 2.87% |
| Dec 28, 1997 | 90,500 | 1,200 | 1.34% |
| Dec 29, 1996 | 89,300 | 7,000 | 8.51% |
| Dec 31, 1995 | 82,300 | 800 | 0.98% |
| Dec 31, 1994 | 81,500 | -100 | -0.12% |
| Dec 31, 1993 | 81,600 | -3,300 | -3.89% |
| Dec 31, 1992 | 84,900 | 2,200 | 2.66% |
| Dec 31, 1991 | 82,700 | 500 | 0.61% |
| Dec 31, 1990 | 82,200 | -900 | -1.08% |
| Dec 31, 1989 | 83,100 | 1,800 | 2.21% |
| Dec 31, 1988 | 81,300 | 3,100 | 3.96% |
| Dec 31, 1987 | 78,200 | 1,100 | 1.43% |
| Dec 31, 1986 | 77,100 | 2,200 | 2.94% |
| Dec 31, 1985 | 74,900 | 700 | 0.94% |
| Dec 31, 1984 | 74,200 | -3,200 | -4.13% |
| Dec 31, 1983 | 77,400 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
JNJ News
- 23 hours ago - GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities - Seeking Alpha
- 1 day ago - 5 defensive stocks traders are buying before the Fed rate-cut decision - Invezz
- 1 day ago - 1 Major Factor Behind the Healthcare Sector's Recent Surge - The Motley Fool
- 1 day ago - Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma - PRNewsWire
- 2 days ago - Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 days ago - Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma - PRNewsWire
- 5 days ago - Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC - PRNewsWire
- 7 days ago - Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha